Efficacy of temozolomide or dacarbazine in combination with an anthracycline for rescue chemotherapy in dogs with lymphoma

Journal of the American Veterinary Medical Association

Volumn 231, Issue 4, 2007, Pages 563-569

  Dervisis, Nikolaos G ^a   Dominguez, Pedro A ^a   Sarbu, Luminita ^a   Newman, Rebecca G ^a   Cadile, Casey D ^a   Swanson, Christine N ^a   Kitchell, Barbara E ^a  

^a MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; DACARBAZINE; DRUG DERIVATIVE; TEMOZOLOMIDE;

ANIMAL; ANIMAL DISEASE; ARTICLE; CANCER STAGING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOG; DOG DISEASE; DRUG RESISTANCE; FEMALE; LYMPHOMA; MALE; SURVIVAL; TIME; TREATMENT OUTCOME; TUMOR RECURRENCE;

ANIMALS; ANTHRACYCLINES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DACARBAZINE; DOG DISEASES; DOGS; DRUG RESISTANCE, NEOPLASM; FEMALE; LYMPHOMA; MALE; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME;

ANIMALIA; CANIS FAMILIARIS;

EID: 34547854682     PISSN: 00031488     EISSN: None     Source Type: Journal    
DOI: 10.2460/javma.231.4.563     Document Type: Article

References (24)

1. Van Vechten M, Helfand SC, Jeglum KA. Treatment of relapsed canine lymphoma with doxorubicin and dacarbazine. J Vet Intern Med 1990;4:187-191.
2. Remmelink M, Salmon I, Delville JP, et al. In vitro characterisation of soft tissue tumor chemosensitivity. Anticancer Res 1997;17:2009-2017.
3. Leikin S, Bernstein I, Evans A, et al. Use of combination adriamycin (NSC-123127) and DTIC (NSC-45388) in children with advanced stage IV neuroblastoma. Cancer Chemother Rep 1975;59:1015-1018.
4. Mellanby RJ, Herrtage ME, Dobson JM. Owners' assessments of their dog's quality of life during palliative chemotherapy for lymphoma. J Small Anim Pract 2003;44:100-103.
5. Ahaus EA, Couto CG, Valerius KD. Hematological toxicity of doxorubicin-containing protocols in dogs with spontaneously occurring malignant tumors. J Am Anim Hosp Assoc 2000;36:422-426.
6. Gray KN, Raulston GL, Gleiser CA, et al. Histologic classification as an indication of therapeutic response in malignant lymphoma of dogs. J Am Vet Med Assoc 1984;184:814-817.
7. Stevens MF, Hickman JA, Stone R, et al. Antitumor imidazotetrazines. 1. Synthesis and chemistry of 8-carbamoyl-3-(2-chloroethyl)imidazo[5,1-d]-1,2,3,5- tetrazin-4(3 H)-one, a novel broad-spectrum antitumor agent. J Med Chem 1984;27:196-201.
8. Tsang LL, Quarterman CP, Gescher A, et al. Comparison of the cytotoxicity in vitro of temozolomide and dacarbazine, pro-drugs of 3-methyl-(triazen-1-yl) imidazole-4-carboxamide. Cancer Chemother Pharmacol 1991;27:342-346.
9. Stevens MF, Hickman JA, Langdon SP, et al. Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5- tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine. Cancer Res 1987;47:5846-5852.
10. Reid JM, Kuffel MJ, Miller JK, et al. Metabolic activation of dacarbazine by human cytochromes P450: the role of CYP1A1, CYP1A2, and CYP2E1. Clin Cancer Res 1999;5:2192-2197.
11. Veterinary Cooperative Oncology Group. Common terminology criteria for adverse events (VCOGCTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.0. Vet Comp Oncol 2004;2:195-213.
12. Kim HK, Lin CC, Parker D, et al. High-performance liquid chromatographic determination and stability of 5-(3-methyltriazen-1-yl)-imidazo-4-carboximide, the biologically active product of the antitumor agent temozolomide, in human plasma. J Chromatogr B Biomed Sci Appl 1997;703:225-233.
13. Initial scientific discussion for the approval of Temodal. European Medicines Agency Web site. Available at: www.emea.europa.eu/humandocs/PDFs/EPAR/ Temodal/274198en6.pdf. Accessed Jan 1, 2007.
14. Neff T, Beard BC, Peterson LJ, et al. Polyclonal chemoprotection against temozolomide in a large-animal model of drug resistance gene therapy. Blood 2005;105:997-1002.
15. Newlands ES, Blackledge GR, Slack JA, et al. Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856). Br J Cancer 1992;65:287-291.
16. Dhodapkar M, Rubin J, Reid JM, et al. Phase I trial of temozolomide (NSC 362856) in patients with advanced cancer. Clin Cancer Res 1997;3:1093-1100.
17. Loar AS, Susaneck SJ. Doxorubicin-induced cardiotoxicity in five dogs. Semin Vet Med Surg (Small Anim) 1986;1:68-71.
18. Hammer AS, Couto CG, Filppi J, et al. Efficacy and toxicity of VAC chemotherapy (vincristine, doxorubicin, and cyclophosphamide) in dogs with hemangiosarcoma. J Vet Intern Med 1991;5:160-166.
19. Yung WK, Prados MD, Yaya-Tur R, et al. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. J Clin Oncol 1999;17:2762-2771.
20. Calvert CA, Leifer CE. Doxorubicin for treatment of canine lymphosarcoma after development of resistance to combination chemotherapy. J Am Vet Med Assoc 1981;179:1011-1012.
21. Hohenhaus AE, Matus RE. Etoposide (VP-16). Retrospective analysis of treatment in 13 dogs with lymphoma. J Vet Intern Med 1990;4:239-241.
22. Moore AS, Ogilvie GK, Vail DM. Actinomycin D for reinduction of remission in dogs with resistant lymphoma. J Vet Intern Med 1994;8:343-344.
23. Rassnick KM, Mauldin GE, Al-Sarraf R, et al. MOPP chemotherapy for treatment of resistant lymphoma in dogs: a retrospective study of 117 cases (1989-2000). J Vet Intern Med 2002;16:576-580.
24. Alvarez FJ, Kisseberth WC, Gallant SL, et al. Dexamethasone, melphalan, actinomycin D, cytosine arabinoside (DMAC) protocol for dogs with relapsed lymphoma. J Vet Intern Med 2006;20:1178-1183.